Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases.

Pharmaceutical

Allegro Ophthalmics

Allegro Ophthalmics' headquarters in San Juan Capistrano, CA, United States

Vicken Karageozian

John Park

Michele Gray

Melvin Sarayba

Hampar Karageozian

David S. Boyer

Hugo Quiroz-Mercado

Richard L. Lindstrom

William J. Link

Ron Kurtz

Marc Carlson

Rebecca Colbert

Jeffrey S. Heier

Julie Kornfield

Peter K. Kaiser

Barry Kuppermann

Eric D. Donnenfeld

Edward J. Holland

Peter Campochiaro

The Scientific Advisors - Retina and Cornea team at Allegro Ophthalmics provides expert guidance on the development and application of integrin inhibition therapies for treating retinal and corneal diseases. They leverage their specialized knowledge to support clinical trials, inform drug development strategies, and ensure the efficacy and safety of new ophthalmic treatments.

Scientific Advisors - Retina and Cornea

The Leadership Team at Allegro Ophthalmics is responsible for setting the strategic direction and overseeing the execution of the company's innovative development in integrin inhibition therapy. They lead cross-functional initiatives, drive clinical and manufacturing advancements, and ensure alignment with regulatory standards to effectively bring transformative treatments for retinal diseases to market. Their combined expertise shapes the company’s vision and fosters a collaborative environment for scientific and operational excellence.

Leadership Team

Allegro Ophthalmics

Org chart

Board & advisors

Teams

Scientific Advisors - Retina and Cornea

Leadership Team

Offices

Allegro Ophthalmics

Org chart

Board & advisors

Teams

Scientific Advisors - Retina and Cornea

Leadership Team

Offices

Related companies